Nurix Therapeutics to Participate in Upcoming Investor Conferences

Rhea-AI Summary

Nurix Therapeutics (Nasdaq: NRIX), a biopharmaceutical company focused on developing targeted protein modulation therapies for cancer, announced key participation in November conferences. CEO Arthur T. Sands will present at:

• Credit Suisse 31^st Annual Healthcare Conference on November 8, 11:25 - 11:55 a.m. ET.
• Piper Sandler 34^th Annual Healthcare Conference on November 30, 4:30 - 4:55 p.m. ET.

The events will be webcast and available on the company's website for about 30 days afterward.

SAN FRANCISCO, Nov. 02, 2022 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a biopharmaceutical company developing targeted protein modulation drugs designed to treat patients with hematologic malignancies and solid tumors, today announced that Arthur T. Sands, M.D., Ph.D., Nurix’s president and chief executive officer, will participate in the following conferences in November:

• Credit Suisse 31^st Annual Healthcare Conference
  Presentation date and time: Tuesday, November 8 at 11:25 – 11:55 a.m. ET
• Piper Sandler 34^th Annual Healthcare Conference
  Fireside chat date and time: Wednesday, November 30 at 4:30 – 4:55 p.m. ET
  

The events will be webcast live and may be accessed via a link in the Investors section of the Nurix website under Events and Presentations. An archived copy of the webcast will be available on the Nurix website for approximately 30 days after the event.

About Nurix

Nurix Therapeutics is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of small molecule and cell therapies based on the modulation of cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates targeting E3 ligases, a broad class of enzymes that can modulate proteins within the cell. Nurix’s drug discovery approach is to either harness or inhibit the natural function of E3 ligases within the ubiquitin proteasome system to selectively decrease or increase cellular protein levels. Nurix’s wholly owned pipeline includes targeted protein degraders of Bruton’s tyrosine kinase, a B-cell signaling protein, and inhibitors of Casitas B-lineage lymphoma proto-oncogene B, an E3 ligase that regulates T cell activation. Nurix is headquartered in San Francisco, California. For additional information visit http://www.nurixtx.com/.

Contacts:

Investors

Silinda Neou
Nurix Therapeutics
ir@nurixtx.com

Elizabeth Wolffe, Ph.D.
Wheelhouse Life Science Advisors
lwolffe@wheelhouselsa.com

Media
Brett Whelan
LifeSci Communications
bwhelan@lifescicomms.com

FAQ

What is Nurix Therapeutics' stock symbol?

Nurix Therapeutics is traded under the stock symbol NRIX.

When is the Credit Suisse Healthcare Conference presentation?

The Credit Suisse 31st Annual Healthcare Conference presentation is on November 8, 2022, at 11:25 a.m. ET.

When will Arthur T. Sands speak at the Piper Sandler Healthcare Conference?

Arthur T. Sands will participate in a fireside chat at the Piper Sandler 34th Annual Healthcare Conference on November 30, 2022, at 4:30 p.m. ET.

How can I access the Nurix Therapeutics conference webcasts?

The conference webcasts can be accessed via the Investors section of the Nurix website.

What is the focus of Nurix Therapeutics' research?

Nurix Therapeutics focuses on developing therapies that modulate cellular protein levels to treat cancer and other diseases.